Pretreatment of BMSCs with TZD solution decreases the proliferation rate of MCF-7 cells by reducing FGF4 protein expression

The present study aimed to investigate the effects of bone marrow-derived mesenchymal stem cells (BMSCs) that had been pretreated with pioglitazone and/or rosiglitazone on the growth and proliferation rate of MCF-7 cells. The adhesive interaction between the BMSCs and the MCF-7 cancer cells revealed that the pretreatment of BMSCs with a combination of two types of thiazolidinedione drug reduced the growth and proliferation rate of the MCF-7 cells. The proliferation rate of the MCF-7 cells could also be reduced by the non-adhesive interaction of the cancer cells with BMSCs pretreated with pioglitazone and/or rosiglitazone. The growth and proliferation rate reduction effects on the MCF-7 cells may be attributed to the reduction in the protein level of fibroblast growth factor 4 (FGF4) in the conditioned medium of the pretreated BMSCs. The evidence that the low protein level of FGF4 in the conditioned medium of the pretreated BMSCs perturbed the proliferation rate of the MCF-7 cells by reducing the levels of Ki-67 and proliferating cell nuclear antigen transcripts in the cancer cells was also demonstrated in the present study using a FGF4-neutralizing antibody. All the above findings demonstrate that future studies on the correlation between FGF4 and pretreated BMSCs would be beneficial.

[1]  M. Costello,et al.  Relationship between CCL5 and transforming growth factor-β1 (TGFβ1) in breast cancer. , 2011, European journal of cancer.

[2]  G. Dontu,et al.  Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. , 2011, Cancer research.

[3]  B. Timmons,et al.  Effects of recovery method after exercise on performance, immune changes, and psychological outcomes. , 2010, The Journal of orthopaedic and sports physical therapy.

[4]  M. Weiss,et al.  A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. , 2009, Tissue engineering. Part A.

[5]  D. Rimm,et al.  High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. , 2008, Human Pathology.

[6]  M. Jasnis,et al.  Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3 , 2008, BMC Cancer.

[7]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[8]  Matthew J. Craig,et al.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. , 2007, Neoplasia.

[9]  A. Ben-Baruch,et al.  The Chemokine CCL5 as a Potential Prognostic Factor Predicting Disease Progression in Stage II Breast Cancer Patients , 2006, Clinical Cancer Research.

[10]  D. Peehl,et al.  Expression of CCL5 (RANTES) and CCR5 in prostate cancer , 2006, The Prostate.

[11]  H. Schöler,et al.  Developmental cell biology: Regulatory networks in embryo-derived pluripotent stem cells , 2005, Nature Reviews Molecular Cell Biology.

[12]  F. Balkwill,et al.  A chemokine receptor antagonist inhibits experimental breast tumor growth. , 2003, Cancer research.

[13]  P. Goss,et al.  The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. , 2003, The Biochemical journal.

[14]  K. Possinger,et al.  PPARγ Ligands and ATRA Inhibit the Invasion of Human Breast Cancer Cells in vitro , 2003, Breast Cancer Research and Treatment.

[15]  R Bicknell,et al.  Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. , 2000, Cancer research.

[16]  H. Hombauer,et al.  Selective interactions between epithelial tumour cells and bone marrow mesenchymal stem cells , 2000, British Journal of Cancer.

[17]  A. Rizzino,et al.  Effects of differentiation on the transcriptional regulation of the FGF‐4 gene: Critical roles played by a distal enhancer , 1998, Molecular reproduction and development.

[18]  D. Birnbaum,et al.  Localization of the 5' end of the MCF2 oncogene to human chromosome 15q15----q23. , 1992, Cytogenetics and cell genetics.

[19]  K. Possinger,et al.  PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. , 2003, Breast cancer research and treatment.